EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901. EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wAMD). It is the newest of several sustained delivery drugs under study, this one promising to extend [Read More]
Author: Dan Roberts
Faricimab for wet AMD effective at 16-week intervals
Genentech has announced positive topline results from its Phase III studies, TENAYA and LUCERNE, evaluating its new drug faricimab, for people with wet (neovascular) age-related macular degeneration (nAMD). Both studies have shown that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes as effective as those receiving [Read More]
Looking Forward to 2021
Even the most optimistic person will admit that 2020 was a 365-day slog through dangers, disasters, and disappointments. In a year that offered little relief, considering that its famous number might have been expected to boost our spirits with good news about vision. And that’s why it might help us to look ahead at some [Read More]
Headworn Video Devices Are Helping The Visually Impaired To See Better
by Dan Roberts Portable electronic magnifiers have come a long way in the past decade, improving clarity of vision for thousands. A natural development for those who prefer to have their hands free has been the creation of several types of headworn video devices, the leaders in the field being eSight, NuEyes, and IrisVision. These [Read More]
A Self-Help Guide to Non-Visual Skills
If you are in the intermediate to late stage of vision loss, you may be considering making the transition from visual to nonvisual practices in some of your daily activities. Low vision rehabilitation is designed to address those challenges, but if such services are unavailable to you, this guide may be helpful. Twenty-one categories of [Read More]